Home
Resource
Understanding the anti-cancer activities of Moringa isothiocyanates in breast cancer cells
PDF
PDF format is widely accepted and good for printing.
Plug-in required
PDF-1(2.06 MB)
Citation & Export
View Usage Statistics
Staff View

Citation & Export
Hide

Simple citation

Olayanju, Julia Bolanle. Understanding the anti-cancer activities of Moringa isothiocyanates in breast cancer cells. Retrieved from https://doi.org/doi:10.7282/T3W66Q7B

Export

Click here for information about Citation Management Tools at Rutgers.

Statistics
Hide

Description

TitleUnderstanding the anti-cancer activities of Moringa isothiocyanates in breast cancer cells
NameOlayanju, Julia Bolanle (author); Ganesan, Shridar (chair); Xia, Bing (internal member); Drake, Justin (internal member); Walworth, Nancy (outside member); Rutgers University; School of Graduate Studies
Date Created2018
Other Date2018-05 (degree)
SubjectMicrobiology and Molecular Genetics, Moringa oleifera, Breast--Cancer
Extent1 online resource (xii, 87 p. : ill.)
DescriptionIsothiocyanates (ITCs) are a class of naturally occurring compounds shown to have anti-cancer activities and promising chemopreventive prospects. Moringa oleifera (MO), a cruciferous vegetable widely cultivated in the tropics, has been used by locals to treat different diseases for centuries. Moringa Isothiocyanates (MIC) is produced from MO when the four unique sugar-modified aromatic glucosinolates it contains are hydrolyzed in a reaction catalyzed by myrosinase. In this study, we evaluated the efficacy of MIC on 9 different breast cancer cell lines and found it to be a potent anti-cancer agent. Interestingly, two of the most sensitive cells lines to MIC, BT474 and HCC1954, were both positive for HER2. HER2 is amplified in up to 30% of breast cancers and is positively correlated with poor prognosis in patients. We hypothesized that HER2 overexpression induces hypersensitivity to MIC in breast cancer cells. Our studies using MCF7 and MDA-MB-231 with and without HER2 overexpression further confirmed the correlation between HER2 overexpression and hypersensitivity to MIC. To understand why increased sensitivity to MIC was observed in HER2+ breast cancer cell lines as compared to HER2- cell lines, intracellular levels of reactive oxygen species (ROS) was examined. Higher basal intracellular ROS levels were observed in HER2+ cell lines compared to HER2- ones. We also hypothesized that the anti-cancer activity of MIC may involve an ROS regulatory pathway. Indeed, we found that MIC clearly regulates NRF2 and KEAP1 expression in multiple breast cancer cell lines. Additionally, MIC also triggers changes in intracellular ROS levels in a cell line-dependent manner, suggesting that MIC adopts different mechanisms of action in different breast cancer cell lines. Our work shows that MIC may open new frontiers in breast cancer prevention and therapy, particularly for those with HER2 amplification.
NotePh.D.
NoteIncludes bibliographical references
Noteby Julia Bolanle Olayanju
Genretheses, ETD doctoral
Persistent URLhttps://doi.org/doi:10.7282/T3W66Q7B
Languageeng
CollectionSchool of Graduate Studies Electronic Theses and Dissertations
Organization NameRutgers, The State University of New Jersey
RightsThe author owns the copyright to this work.
Version 8.5.5
Rutgers University Libraries - Copyright ©2024